Allelica builds fast, efficient and scalable software to implement clinically accessible polygenic risk scores (PRSs). Its technology combines large datasets and advanced algorithms to generate PRSs for diseases including coronary artery disease, breast, prostate and colon cancers, Type 2 diabetes and Alzheimer’s disease. Allelica’s tools aim to translate genomic data into practical risk‑stratification used for preventative medicine and early intervention. The company cites a publication in Circulation showing how its PRS for coronary artery disease can alter clinical risk assessments tied to LDL cholesterol. Allelica has commercial traction, including several customers and a partnership with Merck to develop cardiovascular disease prevention tools. The company recently raised seed financing to advance clinical integration of its PRS software into US healthcare systems and relocated its headquarters to New York City.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2021